New strategies to develop new medications for lung cancer and metastasis

Yujie Zhao, Alex Adjei

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.

Original languageEnglish (US)
Pages (from-to)265-275
Number of pages11
JournalCancer and Metastasis Reviews
Volume34
Issue number2
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Lung Neoplasms
Neoplasm Metastasis
Non-Small Cell Lung Carcinoma
Survival
Therapeutics
Genomics
Molecular Biology
Neoplasms

Keywords

  • ALK
  • CTLA-1
  • EGFR
  • Immunotherapy
  • Lung cancer
  • NSCLC
  • PD-1
  • PD-L1
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

New strategies to develop new medications for lung cancer and metastasis. / Zhao, Yujie; Adjei, Alex.

In: Cancer and Metastasis Reviews, Vol. 34, No. 2, 01.06.2015, p. 265-275.

Research output: Contribution to journalArticle

@article{c39fec37118141179dfef837305758a1,
title = "New strategies to develop new medications for lung cancer and metastasis",
abstract = "With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.",
keywords = "ALK, CTLA-1, EGFR, Immunotherapy, Lung cancer, NSCLC, PD-1, PD-L1, Tyrosine kinase inhibitors",
author = "Yujie Zhao and Alex Adjei",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s10555-015-9553-5",
language = "English (US)",
volume = "34",
pages = "265--275",
journal = "Cancer and Metastasis Reviews",
issn = "0167-7659",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - New strategies to develop new medications for lung cancer and metastasis

AU - Zhao, Yujie

AU - Adjei, Alex

PY - 2015/6/1

Y1 - 2015/6/1

N2 - With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.

AB - With the advances in cancer and molecular biology and the rapid progress in genomics, significant progress has been made in the treatment of lung cancer in the past decade. Targeted therapies have been developed for nonsmall cell lung cancer (NSCLC), and significant improvement in survival has been achieved. There is still, however, no cure for advanced NSCLC. Resistance to initial therapy is universal, and the lethal outcome of metastatic disease still remains. Approaches to preventing metastases and overcoming resistance to therapy are necessary to ensure long-term survival of patients with advanced lung cancer.

KW - ALK

KW - CTLA-1

KW - EGFR

KW - Immunotherapy

KW - Lung cancer

KW - NSCLC

KW - PD-1

KW - PD-L1

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84938416631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938416631&partnerID=8YFLogxK

U2 - 10.1007/s10555-015-9553-5

DO - 10.1007/s10555-015-9553-5

M3 - Article

C2 - 25944554

AN - SCOPUS:84938416631

VL - 34

SP - 265

EP - 275

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 2

ER -